slide1 n.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
Director’s Report to the National Advisory Council on Drug Abuse PowerPoint Presentation
Download Presentation
Director’s Report to the National Advisory Council on Drug Abuse

Loading in 2 Seconds...

play fullscreen
1 / 60

Director’s Report to the National Advisory Council on Drug Abuse - PowerPoint PPT Presentation


  • 141 Views
  • Uploaded on

Director’s Report to the National Advisory Council on Drug Abuse. February 8, 2006. Director’s Report to the National Advisory Council on Drug Abuse. Budget Update. What’s New @ NIH?. Recent NIDA Activities. Science Findings. Budget Update. NIDA BUDGET. (Thousands). 2007 PB.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Director’s Report to the National Advisory Council on Drug Abuse' - belva


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
slide1

Director’s Report to the

National Advisory Council

on Drug Abuse

February 8, 2006

slide2

Director’s Report to the

National Advisory Council on Drug Abuse

Budget Update

What’s New @ NIH?

Recent NIDA Activities

Science Findings

slide4

NIDA BUDGET

(Thousands)

2007PB

2005Actual

2006Approp.

$693,282

$699,956

$695,563

$299,266

$994,829

NonAIDS

$313,137

$300,073

AIDS

$1,006,419

$1,000,029

TOTAL

Increase Over Prior Year

+1.2%

-0.6%

-0.5%

slide6

First Major Independent Research Support Occurs at an Ever-Later Age

Average Age of Initial Type 1 R01/R23/R29 Award

for Different Degrees Held

45

44

44

43

42

42

M.D.-Ph.D.

41

M.D.

Average age

40

40

Ph.D.

39

38

38

37

37

36

35

1980

1981

1982

1983

1984

1985

1986

1987

1988

1989

1990

1991

1992

1993

1994

1995

1996

1997

1998

1999

2000

2001

2002

2003

Fiscal Year

For more information, see http://grants.nih.gov/grants/20040712_New_Investigator_Talk.ppt

slide7

New Investigators Program

NIH is Committed to Providing Pathways to

Research

Independence

For New

Investigators

Pathway to

Independence

Award

NRSA Individual

and Institutional

Training Awards

Career

Development

Awards

Research

Project Grant

Program

NIH Institute

and Center

Practices

Resources

for New

Investigators

NIH Pathway to Independence Award Program

  • Announced January 27, 2006
  • Opportunity for promising postdoctoral scientists to receive both
  • mentored and independent research support from the same award
  • Responsive to NAS 2005 Report “Bridges to Independence”
  • Beginning in Fall 2006 NIH plans to issue 150 to 200 awards/year
  • for the next 5 years
slide8

ENHANCING THE VITALITY OF THE

NATIONAL INSTITUTES OF HEALTH:

Organizational Change to Meet New Challenges

NATIONAL ACADEMY OF SCIENCES

INSTITUTE OF MEDICINE

Recommendations Focused On

OptimizingFunction Rather

Than Changing Structure

The NIH Office of

Portfolio Analysis &

Strategic Initiatives

(OPASI)

why does nih need opasi
Why Does NIH Need OPASI?
  • Need for coordinated assessment and

management of the overall portfolio of

NIH-funded research

  • Need for transparent, systematic processes for:
    • Coding of specific diseases and conditions
    • Assessing scientific opportunities and public health needs and

integrating them into NIH-wide funding priorities

    • Coordinating funding of research areas that cut across or fall

between the missions of individual Institutes and Centers

how does opasi select and implement trans nih research
How Does OPASI Select and Implement Trans-NIH Research?
  • Proposals are reviewed by:
    • OPASI leadership
    • Institute and Center (IC) Directors
    • Council of Councils
    • Advisory Committee to the Director (ACD)
    • NIH Director
  • Once approved for funding:
    • Initiatives are assigned to a lead IC or ICs
    • Research is supported by the Common Fund
common fund for shared needs
Common Fund for Shared Needs
  • Fund initiatives that are in areas of interest to multiple ICs
  • Current Roadmap funds will serve as the baseline for the Common Fund: 1.1% of the total NIH budget in FY 2006, growing to ~1.7% in FY 2008
  • Future growth of the Common Fund:
    • No growth above the FY 2008 percent until the annual NIH budget increase exceeds Biomedical Research and Development Price Index (BRDPI)
    • Rate of growth will be determined annually by NIH Director and IC Directors
    • Common Fund will increase up to 5% of the total NIH budget
slide14

NIDA Basic Science Review Workgroup

First Meeting November 17-18, 2005

Second Meeting March 2006

NIDA Council

Members

Linda Porrino, Ph.D, Chair

Barry Lester, Ph.D.

John P. Rice, Ph.D.

Frank Ivy Carroll, Ph.D

Yasmin Hurd, Ph.D.

Guy Cabral, Ph.D.

Stanley Watson, M.D., Ph.D.

Marina Picciotto, Ph.D.

Michael Nader, Ph.D.

Kathryn Cunningham, Ph.D.

slide15

NIDA Basic Science Review Workgroup

Charge: To produce a written report that includes…

  • Review of the current Basic Science program portfolio
  • Recommendations to strengthen the current program
  • Input into the 5-year plan for NIDA’s Basic Science program
  • with an emphasis on:
  • Genetic vulnerability and protection
  • Epigenetics (interactions of environment and genetics)
  • The genetics and neurobiology of social behavior
  • Molecular biology of addiction
  • Examination of the organization and management of DNBR and its interactions with other NIDA Divisions/Centers
slide16

NIDA’s Approach to Grant-Making Work Group

First Meeting December 6-7, 2005

Second Meeting February 7, 2006

NIDA Council

Members

Scott Lucas, Ph.D.

Kathleen Carroll, Ph.D.

Tom Kosten, M.D.

Constance Weisner, Dr.P.H., M.S.W., Chair

David Vlahov, Ph.D.

Claire E. Sterk, Ph.D.

Mark Greenberg, Ph.D.

Rodolfo Arredondo, Jr., Ed.D.

Linda Porrino, Ph.D.

slide17

NIDA’s Approach to Grant-Making Work Group

Charge: To produce a written report and determine if any

actions or new policies may be needed on the following…

  • Recommendations to ensure that in this age of restricted
  • budgets we protect young investigators
  • Balance between “large” versus “small” science at NIDA
  • Guidelines regarding PI with multiple grants (NIDA or other
  • IC) or laboratories with multiple grants
  • Recommendations regarding length of duration of grants
  • (R01s, Centers, program projects)
slide18

Social Neuroscience (RFA-DA-06-004)

(With Canadian Institutes of

Health Research (CIHR))

Released November 10, 2005

Application receipt Date: February 23, 2006

slide19

Prescription Opioid Use and Abuse

in the Treatment of Pain

(RFA-DA-06-005) (with NIA and NIDCR)

Released November 18, 2005

Application Receipt Date: February 23, 2006

slide20

PAs and RFAs Issued

With Other NIH Components/Agencies

29 New PAs and 11 New RFAs

  • Foci include:
  • Neuroimaging
  • HIV/AIDS
  • Biotechnology
  • Dissemination & Implementation
  • Research Training
slide21

NIDA

National Institute on Drug Abuse

Office of the Director

Nora D. Volkow, MD

Director

Director, AIDS Research

HIV/AIDS Research

Special Populations Office

Timothy P. Condon, Ph.D.

Deputy Director

Laura S. Rosenthal

Associate Director

for Management

Office of

Extramural

Affairs

Office of Planning

& Resource

Management

Office of

Science Policy &

Communications

Center for the

Clinical Trials

Network

Teresa Levitin, PhD

Laura Rosenthal

Timothy Condon, PhD

Betty Tai, PhD

Division of

Epidemiology,

Services &

Prevention Research

Division of

Pharmacotherapies &

Medical Consequences

of Drug Abuse

Division of

Basic Neurosciences

& Behavior Research

Intramural

Research

Program

Division of Clinical

Neuroscience &

Behavioral Research

David Shurtleff, PhD

Frank Vocci, PhD

Wilson Compton, MD, MPE

Joseph Frascella, PhD

Barry Hoffer, MD, PhD

slide22

HIV/AIDS and Drug Abuse:

The Complexities of Linked Epidemics

Press Conference & Science Meeting

National Press Club

November 29, 2005

slide24

NIDA

National Institute on Drug Abuse

Office of the Director

Nora D. Volkow, MD

Special Population/

Health Disparities

Director

Director, AIDS Research

Special Populations Office

Timothy P. Condon, Ph.D.

Deputy Director

Laura S. Rosenthal

Associate Director

for Management

Office of

Extramural

Affairs

Office of Planning

& Resource

Management

Office of

Science Policy &

Communications

Center for the

Clinical Trials

Network

Teresa Levitin, PhD

Laura Rosenthal

Timothy Condon, PhD

Betty Tai, PhD

Division of

Epidemiology,

Services &

Prevention Research

Division of

Pharmacotherapies &

Medical Consequences

of Drug Abuse

Division of

Basic Neurosciences

& Behavior Research

Intramural

Research

Program

Division of Clinical

Neuroscience &

Behavioral Research

David Shurtleff, PhD

Frank Vocci, PhD

Wilson Compton, MD, MPE

Joseph Frascella, PhD

Barry Hoffer, MD, PhD

slide25

National Institute on Drug Abuse

Health Disparities Conference

  • Nearly 400 participants
  • Plenary sessions addressed
  • HIV/AIDS
  • Criminal Justice Concerns
  • Other Issues in Health
  • Disparities Research Related
  • to Drug Use
  • Meeting Outcomes included:
  • Discussion of collaborations between investigators,
  • Established mentorship with students
  • Increased awareness of opportunities with NIDA
  • through grant development workshops
slide26

Administrative Supplements for Research on the

Intersection of Drug Use and Criminal Justice

Consequences in the African American Population

6 Supplements Awarded

Health Disparities in HIV/AIDS: Focus on

African Americans (R01) (PA-06-069)

(with NIMH)

Released November 10, 2005

Drug Abuse as a Cause, Correlate, or

Consequence of Criminal Justice Related

Health Disparities Among African Americans

(R01) (PA-06-068)

Released November 10, 2005

slide27

NIDA

National Institute on Drug Abuse

Office of the Director

Nora D. Volkow, MD

Director

Director, AIDS Research

Special Populations Office

Timothy P. Condon, Ph.D.

Deputy Director

Laura S. Rosenthal

Associate Director

for Management

Office of

Extramural

Affairs

Office of Planning

& Resource

Management

Office of

Science Policy &

Communications

Center for the

Clinical Trials

Network

Teresa Levitin, PhD

Laura Rosenthal

Timothy Condon, PhD

Betty Tai, PhD

Division of

Epidemiology,

Services &

Prevention Research

Division of

Pharmacotherapies &

Medical Consequences

of Drug Abuse

Division of

Basic Neurosciences

& Behavior Research

Division of Clinical

Neuroscience &

Behavioral Research

Intramural

Research

Program

DPMCDA

David Shurtleff, PhD

Frank Vocci, PhD

Wilson Compton, MD, MPE

Joseph Frascella, PhD

Barry Hoffer, MD, PhD

slide28

Design, Synthesis and Preclinical Testing

of Potential Treatment Agents

for Drug Addiction (PAS-06-066)

Released November 9, 2005

slide29

Methylphenidate

p=0.0142

3

1

-1

-3

Proportion of Amphetamine Positive

Urines During the 12-Week Period

Placebo

p=0.7869

5 10 15 20

3

1

-1

-3

5 10 15 20

Methylphenidate Was Associated With Significantly

Better Outcomes Than Placebo

Source: Tiihonen, J. presented at NIDA-sponsored meeting “The Methamphetamine Menace” December 10, 2005.

slide30

NIDA

National Institute on Drug Abuse

Office of the Director

Nora D. Volkow, MD

Director

Director, AIDS Research

Special Populations Office

Timothy P. Condon, Ph.D.

Deputy Director

Laura S. Rosenthal

Associate Director

for Management

Office of

Extramural

Affairs

Office of Planning

& Resource

Management

Office of

Science Policy &

Communications

Center for the

Clinical Trials

Network

Teresa Levitin, PhD

Laura Rosenthal

Timothy Condon, PhD

Betty Tai, PhD

Division of

Epidemiology,

Services &

Prevention Research

Division of

Pharmacotherapies &

Medical Consequences

of Drug Abuse

Division of

Basic Neurosciences

& Behavior Research

Intramural

Research

Program

Division of Clinical

Neuroscience &

Behavioral Research

DBNBR

David Shurtleff, PhD

Frank Vocci, PhD

Wilson Compton, MD, MPE

Joseph Frascella, PhD

Barry Hoffer, MD, PhD

slide31

Epigenetics of Neurobiology and Addiction

(RFA-DA-06-007) (With Canadian Institutes

Of Health Research (CIHR))

Released October 2, 2005

Application Receipt Date: January 23, 2006

slide32

NIDA

National Institute on Drug Abuse

Office of the Director

Nora D. Volkow, MD

Director

Director, AIDS Research

Special Populations Office

Timothy P. Condon, Ph.D.

Deputy Director

Laura S. Rosenthal

Associate Director

for Management

Office of

Extramural

Affairs

Office of Planning

& Resource

Management

Office of

Science Policy &

Communications

Center for the

Clinical Trials

Network

Teresa Levitin, PhD

Laura Rosenthal

Timothy Condon, PhD

Betty Tai, PhD

Division of

Epidemiology,

Services &

Prevention Research

Division of

Pharmacotherapies &

Medical Consequences

of Drug Abuse

Division of

Basic Neurosciences

& Behavior Research

Intramural

Research

Program

Division of Clinical

Neuroscience &

Behavioral Research

DESPR

David Shurtleff, PhD

Frank Vocci, PhD

Wilson Compton, MD, MPE

Joseph Frascella, PhD

Barry Hoffer, MD, PhD

slide34

Issues of Concern

Percent of 12th Graders Reporting

Nonmedical Use of OxyContin and Vicodin

in the Past Year Remained High

12.0

10.5

9.5

9.6

9.3

10.0

8.0

Percent

6.0

5.5

5.0

4.5

4.0

4.0

2.0

0.0

OxyContin*

Vicodin

2002

2003

2004

2005

No year-to-year differences are statistically significant.

* Between 2002 and 2005 the abuse of OxyContin by 12th graders increased significantly.

slide35

NIDA

National Institute on Drug Abuse

Office of the Director

Nora D. Volkow, MD

Director

Director, AIDS Research

Special Populations Office

Timothy P. Condon, Ph.D.

Deputy Director

Laura S. Rosenthal

Associate Director

for Management

Office of

Extramural

Affairs

Office of Planning

& Resource

Management

Office of

Science Policy &

Communications

Center for the

Clinical Trials

Network

Teresa Levitin, PhD

Laura Rosenthal

Timothy Condon, PhD

Betty Tai, PhD

Division of

Epidemiology,

Services &

Prevention Research

Division of

Pharmacotherapies &

Medical Consequences

of Drug Abuse

Division of

Basic Neurosciences

& Behavior Research

Intramural

Research

Program

Division of Clinical

Neuroscience &

Behavioral Research

DCNBR

David Shurtleff, PhD

Frank Vocci, PhD

Wilson Compton, MD, MPE

Joseph Frascella, PhD

Barry Hoffer, MD, PhD

slide36

Developmental Centers for

Translational Research on the Clinical

Neurobiology of Drug Addiction

(P20) (RFA-DA-06-006)

Released November 8, 2005

Application Receipt Date: February 23, 2006

slide37

Imaging – Science Track Award for

Research Transition (I/START) (R03)

(PAR-06-092)

Released December 9, 2005

slide38

NIDA

National Institute on Drug Abuse

Office of the Director

Nora D. Volkow, MD

Director

Director, AIDS Research

Special Populations Office

Timothy P. Condon, Ph.D.

Deputy Director

Laura S. Rosenthal

Associate Director

for Management

Office of

Extramural

Affairs

Office of Planning

& Resource

Management

Office of

Science Policy &

Communications

Center for the

Clinical Trials

Network

CCTN

Teresa Levitin, PhD

Laura Rosenthal

Timothy Condon, PhD

Betty Tai, PhD

Division of

Epidemiology,

Services &

Prevention Research

Division of

Pharmacotherapies &

Medical Consequences

of Drug Abuse

Division of

Basic Neurosciences

& Behavior Research

Intramural

Research

Program

Division of Clinical

Neuroscience &

Behavioral Research

David Shurtleff, PhD

Frank Vocci, PhD

Wilson Compton, MD, MPE

Joseph Frascella, PhD

Barry Hoffer, MD, PhD

slide39

Update on New CTN Protocols

  • 1. Starting Treatment with Agonist Replacement Therapies (START): compare the effect of buprenorphine/naloxone
  • and methadone on liver function 10 sites, April 2006
  • 2. Prescription Opioid Addiction Treatment Study (POATS)
  • ~ 12 sites, Spring 2006
  • Randomized Controlled Trial of Methylphenidate in
  • Adolescents with ADHD and Substance Use Disorders
  • 10 sites,February 2006
  • 4. Methylphenidate in Maintaining Abstinence in Smokers
  • with ADHD 6 sites, 255 pre-screened; 52 consented; 16 randomized
  • Protocol to assess the utility of 12-Step Facilitation in
  • increasing 12-Step participation and improving drug abuse treatment outcomes (in cocaine and meth abusers) under development
slide41

NIH Roadmap

ACCELERATING MEDICAL DISCOVERY TO IMPROVE HEALTH

NIH Roadmap Activities

slide42

Exploring NIDA’s Opportunities in the

NIH Roadmap Molecular Libraries Project

October 18 and 19, 2005

  • Primary Recommendations:
  • Improve public relations for the
  • Molecular Library/Molecular Imaging (ML/MI) Program
  • Provide incentives for participation in the initiatives
slide43

Integration of Clinical Research Networks

  • Clinical Research Training and Career Development
  • Harmonization of Clinical Research Policy
  • Institutional Clinical and Translation Science Awards
  • Interdisciplinary Research (within the Roadmap
  • theme: Research Teams of the Future)
slide44

LNI

for Neuroscience Research

Neuroscience Information Framework

NIH Goal:

To develop a comprehensive,

dynamic inventory of

Web-accessible neuroscience

information resources that

span multiple levels of

biological function

Laboratory of

Neuroinformatics

Weill Medical College

of Cornell University

SOCIETY FOR NEUROSCIENCE

PI -- Daniel Gardner

  • Five Groups – at Caltech, Cornell, UCSD, George Mason,
  • and Yale– have partnered with the SfN and with volunteer
  • collaborators at nine additional sites to develop:
  • The Framework
  • Terminology/Ontology for neuroscience
  • A content-based query tool

Phase I began September 30, 2005

slide45

for Neuroscience Research

RFAs

Neuroscience Blueprint Interdisciplinary Center Core Grants

(RFA-NS-06-003) -- Issued: September 29, 2005; Application Receipt Date:

January 19, 2006

Development of Recombinase-Expressing (“Driver”) Mouse

Lines for Studying the Nervous System (U01) (RFA-MH-06-007)

Issued November 18, 2005; Application Receipt Date: January 19, 2006

Training in Translational Research in Neurobiology of

Disease (T32) (RFA-DA-06-008) -- Issued November 9, 2005;

Application Receipt Date: February 22, 2006

Training in Computational Neuroscience: From Biology

to Model and Back Again (T90) (RFA-DA-06-101)

Issued: December 16, 2005; Application Receipt Date: March 13, 2006

Training in Neuroimaging: Integrating First Principles

and Applications (T90) (RFA-DA-06-011)

Issued December 23, 2005; Application Receipt Date: March 13, 2006

slide46

Primary Care Physicians Are Often Reluctant

To Treat Substance Abuse or Fail to Link This

With Their Patients’ Other Medical Conditions

  • Mental Illness
  • Cancer
  • Infectious Diseases
  • (HIV, HCV)
  • Cardiac
  • Pulmonary
  • Learning Disorders
  • Obesity
  • Cerebrovascular (strokes)
  • Trauma (accidents)
slide47

NIDA’s Primary Care Outreach Initiative

  • Physician Work Group
  • Establishedto help us craft
  • our activities in this area
  • Workgroup Meeting Held January 27, 2006
  • Physicians’ Page
  • Added to our Website
slide48

and

NIDA

NATIONAL INSTITUTE

ON DRUG ABUSE

Opportunities for Collaboration

  • Create an Interagency Workgroup between
  • FDA and NIDA
  • Re-establish a body of drug abuse expertise
  • similar to the former FDA Drug Abuse Advisory
  • Council (DAAC) chartered from 1978-2002
slide49

Recent Meetings,

Conferences and Events

slide50

Addiction and Obesity – Brain Systems Commonalities

Presentation by the Jacob A. Waletzky Award Recipient

Neurobiological Basis for Co-occurring Substance Abuse

& Mental Illness

Poster Session: Early Career Investigators

mGluR: A Substrate in the Neurobiology of Addiction

Reconsolidation of Memory: A New Approach to Treat

Drug Addiction?

Adolescent Drug Abuse: Brain Development, Cognition

& Vulnerability

November 11, 2005 -- 8:00AM to 9:00PM

slide51

Congressional Briefings, Hearings & Events

Congressional Meth Caucus Roundtable

September 25, 2005 -- Sponsored by members of

the Congressional Caucus to Fight and Control

Methamphetamine

HIV/AIDS & Drug Abuse Hill Briefing

October 25, 2005 -- Sponsored by the Friends of NIDA

and the Chairs of the Congressional Addiction

Treatment & Recovery Caucus

Methamphetamine Hearing

November 17, 2005 – Sponsored by the

House Education and the Workforce

Subcommittee on Education Reform

U.S. Senators’ National Town Hall

on Methamphetamine Awareness &

Prevention

January 23, 2006 – Sponsored by

Senators Colman, Burns, Baucus, Pryor and Hagel

slide53

Cigarettes: Trends in Thirty-Day Prevalence of Use

for Twelfth Graders

Source: Monitoring the Future Study, 2005

slide54

Adolescent Nicotine Metabolism:

Ethnoracial Differences Among Dependent Smokers

Smoking Rate (Cigarettes/day)

Plasma Cotinine (ng/ml)

p= .013

Caucasian

African

American

Caucasian

African

American

Plasma Cotinine: CPD Ratio

Plasma 3-HC: Cotinine Ratio

p= .033

p= .026

Caucasian

African

American

Caucasian

African

American

Source: Moolchan, E.T et al., Ethnicity and Disease, 2006.

slide55

MALDI-IM-oTOF Mass Spectrometer

A custom built mass spectrometer equipped with an ion

mobility cell has been established in the laboratory of

Dr. Amina Woods, NIDA IRP

The instrument was developed through

two DBNBR contracts with Ionwerks

(J. Albert Schultz, PI)

percentage of new investigators in competing r01 awards continues to decrease fy 1962 fy 2003
Percentage of New Investigators in Competing R01 Awards Continues to DecreaseFY 1962 - FY 2003

100%

90%

Established Investigator

80%

70%

60%

50%

40%

New Investigator

30%

2

R

= 0.71

20%

10%

0%

1963

1967

1971

1975

1979

1983

1987

1991

1995

1999

2003

slide57

OD Programmatic Offices

Evaluation

IC Directors

Stakeholders

Scientific Analysis/

Burden of Illness Data

Regular Roadmap-like Process

OPASI

The external community has a voice in proposing AND choosing OPASI initiatives

Council of

Councils

IC

Directors

Advisory Committee

to the Director

NIH

Director

Approval to Fund

Initiative

slide58

Bupropion Reduced Methamphetamine-Induced

Subjective Effects and Cue-Induced Craving

Source: Newton, TF et al., Neuropsychopharmacology Advance online publication November 23, 2005.

slide59

Reward Neurocircuitry

in Adolescent Development

and Decision Making

January 20, 2006

Sponsored By: NIDA, NIMH,

NICHD and NINDS

slide60

To Revitalize their Involvement

We Need to Increase Awareness of

Drug Abuse and Addiction Issues

Among Primary Care Physicians